A Four-Part Phase-1 Study Investigating the Tolerability, Safety and Pharmacokinetics (PK) of MBS2320 in Healthy Subjects and in Subjects With Rheumatoid Arthritis (RA) Also Treated With Methotrexate
Phase of Trial: Phase I
Latest Information Update: 31 Mar 2017
At a glance
- Drugs MBS 2320 (Primary) ; Methotrexate
- Indications Rheumatoid arthritis
- Focus Adverse reactions
- Sponsors Modern Biosciences
- 07 Jun 2017 Biomarkers information updated
- 24 Mar 2017 Status changed from recruiting to completed.
- 10 Nov 2016 Planned End Date changed from 1 Dec 2016 to 1 May 2017.